Abingdon Health PLC Salistick(TM) to be launched in Tesco (2745J)
15 August 2023 - 4:00PM
UK Regulatory
TIDMABDX
RNS Number : 2745J
Abingdon Health PLC
15 August 2023
Abingdon Health plc
("Abingdon Health" or "the Company")
Salistick (TM) , the first ever saliva pregnancy test, to be
launched in Tesco
York, U.K. 15 August 2023: Abingdon Health plc (AIM: ABDX), is
pleased to announce that Tesco will roll-out Salistick(TM), the
first-ever saliva pregnancy test, in 298 stores and online at
Tesco.com from late-August 2023.
The launch of Salistick(TM) will be focused on larger Tesco
stores as well as online at Tesco.com. This follows the initial
launch of Salistick(TM) with Superdrug in 400 stores and online at
Superdrug.com.
The Salistick(TM) pregnancy test offers women an improved user
experience, with high accuracy for early pregnancy detection. The
revolutionary patented technology allows saliva to be used as a
sample rather than the traditional urine sample. Salistick(TM)
offers the ability to test anywhere, anytime, and for the testing
experience to be shared with a partner and other loved ones. It is
estimated that 12.5 million pregnancy tests were performed in the
UK in 2022. The global pregnancy test kits market was valued at USD
1.70 billion in 2022 and is expected to reach USD 2.28 billion by
2028, growing at a CAGR of 5.08%(1) .
Abingdon Health is the exclusive distributor of Salistick(TM) in
the UK and Ireland on behalf of Salignostics Limited, an Israeli
developer of innovative saliva-based diagnostics tests. As well as
providing distribution support Abingdon Health has been providing
Salignostics with contract development services to scale-up the
Salistick(TM) product for manufacture and will continue to provide
Salignostics with contract manufacturing services going
forward.
Chris Yates, CEO of Abingdon Health plc, commented: "We are
delighted to announce the launch of Salistick (TM) with Tesco,
online and rolled-out across nearly 300 larger Tesco stores. This
novel technology provides women with an enhanced user-experience;
offering the ability to test anywhere, anytime, and for the testing
experience to be shared with a partner and other loved ones. We
continue to explore distribution opportunities for Salistick (TM)
both in the UK and internationally and we look forward to launching
the Salistick (TM) dual pack in due course."
Sources:
1. Pregnancy Test Kits Market Size, Share, Trends, Growth Forecast (arizton.com)
Enquiries
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross , Chief Financial Officer
Chris Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000
Nominated Adviser)
Peter Steel, Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Marriage Mob: +44 (0)7980 541 893 / +44 (0)7867
Alice Woodings 984 082
+44 (0)7407 804 654
About Abingdon Health plc
Abingdon Health is a leading lateral flow contract development
and manufacturing organisation ("CDMO") offering its services to an
international customer base across industry sectors that include
clinical, animal health, plant health, and environmental testing.
Abingdon Health has the internal capabilities to take projects from
initial concept through to routine and large-scale manufacturing;
from "idea to commercial success."
The Company's CDMO division offers product development,
regulatory support, technology transfer and manufacturing services
for customers looking to develop new assays or transfer existing
laboratory-based assays to a lateral flow format. Abingdon Health
aims to support the increase in need for rapid results across many
industries and locations and produces lateral flow tests in areas
such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes.
Abingdon Health's Abingdon Simply Test range of self-tests is an
ecommerce platform that offers a range of self-tests to empowers
consumers to manage their own health and wellbeing. The Abingdon
Simply Test ecommerce site offers consumers a range of information
to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract
services customers with a potential route to market for self-tests.
The Abingdon Simply Test range is also sold through international
distributors and through other channels in the UK and Ireland such
as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018. Upon the publication of this announcement
via the Regulatory Information Service, this inside information is
now considered to be in the public domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSFEFILEDSEIA
(END) Dow Jones Newswires
August 15, 2023 02:00 ET (06:00 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2024 to May 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From May 2023 to May 2024